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Acquired mutations in the juxtamembrane region of
MPL (W515K or W515L), the receptor for thrombo-
poietin, have been described in patients with primary
myelofibrosis or essential thrombocythemia, which
are chronic myeloproliferative disorders. We have
developed a real-time polymerase chain reaction as-
say for the detection and quantification of MPL mu-
tations that is based on locked nucleic acid fluores-
cent probes. Mutational analysis was performed using
DNA from granulocytes. Reference curves were ob-
tained using cloned fragments of MPL containing ei-
ther the wild-type or mutated sequence; the predicted
sensitivity level was at least 0.1% mutant allele in a
wild-type background. None of the 60 control subjects
presented with a MPLW515L/K mutation. Of 217 pa-
tients with myelofibrosis, 19 (8.7%) harbored the
MPLW515 mutation, 10 (52.6%) with the W515L al-
lele. In one case, both the W515L and W515K alleles
were detected by real-time polymerase chain reac-
tion. By comparing results obtained with conven-
tional sequencing, no erroneous genotype attribu-
tion using real-time polymerase chain reaction was
found, whereas one patient considered wild type
according to sequence analysis actually harbored a
low W515L allele burden. This is a simple , sensitive ,
and cost-effective procedure for large-scale screen-
ing of the MPLW515L/K mutation in patients sus-
pected to have a myeloproliferative disorder. It can
also provide a quantitative estimate of mutant allele
burden that might be useful for both patient prog-
nosis and monitoring response to therapy. (J Mol
Diagn 2008, 10:435–441; DOI: 10.2353/jmoldx.2008.080015)
The Philadelphia chromosome-negative chronic myelo-
proliferative disorders include polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibro-
sis (PMF).1,2 Their molecular pathogeneses remained
poorly characterized until the description of an acquired
point mutation in exon 14 of JAK2 (V617F), which involves
the substitution of a key valine for a phenylalanine residue
in the JH2 pseudokinase domain.3–6 The frequency of the
JAK2V617F mutation among patients with PV is more
than 95%, whereas approximately half of those who are
V617F-negative harbor different abnormalities located in
JAK2 exon 12.7 On the other hand, approximately 60% of
patients with ET or PMF possess the JAK2V617F mutant.
In 25 to 30% of patients with either PV or PMF, the
JAK2V617F mutation is harbored in a homozygous state
due to mitotic recombination involving the short arm of
chromosome 9.3–6,8 Homozygous patients are rare in ET
and account for only 2 to 4%.9 The burden of the V617F
allele influences disease phenotype9,10 and is associated
with a greater risk of thrombosis in both ET9 and PV11 as
well as with disease progression in PMF.12 This variable
mutation frequency of patients with different clinical phe-
notypes,13 together with the demonstration that at least
certain wild-type JAK2 patients with ET14,15 or PMF (un-
published data) present clonal hematopoiesis using as-
says for the X chromosome inactivation pattern (X-CIP),16
prompted a search for additional mutations in other
genes involved in the JAK2/STAT pathway. Recently, two
novel, recurrent, molecular abnormalities (W515L and
W515K) were identified in MPL, the gene encoding the
receptor for thrombopoietin.17 Thrombopoietin, the main
humoral regulator of thrombopoiesis in humans,18 has
been implicated in the pathogenesis of myelofibrosis in
murine models.19,20 The 515 tryptophan residue is lo-
cated in a unique amphipathic domain of MPL in the
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transmembrane-cytoplasmic hinge region that prevents
spontaneous activation of the receptor.21 In fact, the tryp-
tophan to leucine (WL) substitution confers factor-inde-
pendent growth to Ba/F3 cells that is associated with
constitutive activation of downstream signaling path-
ways.17 Expression of MPLW515L in a murine bone mar-
row transplantation model resulted in an acute myelopro-
liferative disorder phenotype that recapitulated several
aspects of human myelofibrosis.17 In humans, the MPL
mutation occurs in multipotent hematopoietic stem cells,
myeloid cells, purified B and T lymphocytes, and natural
killer cells.22–24
The MPLW515L/K mutation has been detected in 5 to
7% of patients with PMF and in 1% of those with
ET17,25,26; it has not been described in PV or myelodys-
plastic syndromes, including refractory anemia with
ringed sideroblasts and thrombocytosis,27 or in acute
myeloid leukemia.25 The coexistence of theMPLW515L/K
and JAK2V617F mutations in myelofibrosis has also been
reported.25,26,28 In a study of 217 patients with PMF, we
found that this mutation was associated with more severe
anemia and greater transfusion support.26 Therefore, a
search for MPLW515 mutations in either PMF or ET may
have both diagnostic and prognostic implications; in-
deed, the discovery of any of these molecular abnormal-
ities establishes the presence of a clonal myeloprolifera-
tion, representing a major diagnostic criterion in the
recent proposal for revision to the World Health Organi-
zation classification of myeloid neoplasms.2
Previously published assay methods for MPLW515L/K
mutations have been represented by direct sequencing
and melting curve analysis; these methods have a low
sensitivity, unable to detect fewer than 10% and 3%
mutant cells in a wild-type background, respectively, and
are not suitable for high-throughput screening. Therefore,
the aim of this study was to develop a novel real-time
polymerase chain reaction (PCR) assay that could be used
in a large series of patients and would be sensitive enough
to detect a low MPL mutant allele burden. The latter point
might be relevant to novel drugs that target members of
the constitutively activated JAK/STAT pathway, as they
are expected to enter the therapeutic scenario soon.29
This novel real-time PCR assay was validated by retro-
spectively analyzing a population of 217 patients with
myelofibrosis who had been previously genotyped using
direct sequencing.26
Materials and Methods
Patients
The characteristics of 217 patients with myelofibrosis
analyzed in this study were previously described in de-
tail26; 150 patients had PMF, 30 had prefibrotic myelofi-
brosis,1 and 37 had postpolycythemic/post-thrombocy-
themic myelofibrosis. Sixty healthy blood donors were
used as controls. Furthermore, we evaluated 50 patients
with PV who harbor the JAK2V617F mutation and were
diagnosed according to the proposal for revision to the
World Health Organization criteria.2 All patients and con-
trols gave their consent for sample donation and in-
formed consent for the study.
Sample Preparation
Peripheral blood granulocytes were separated by differ-
ential centrifugation over a Ficoll-Ipaque gradient. Briefly,
20 ml of whole blood were collected into EDTA-contain-
ing polypropylene tubes and processed within 4 hours.
Blood was diluted 1:1 with Ca2/Mg2-free phosphate-
buffered saline, carefully layered over 15 ml of Ficoll-
Ipaque in a 50-ml tube, and centrifuged at 800  g at
room temperature for 20 minutes. Both the upper fraction
and the Ficoll layer were carefully removed, while the
lower fraction was collected and transferred to a fresh
tube. Lysis of red blood cells was performed by the addition of
a 10X volume of 1X BDPharmLyse solution (BectonDickinson
BD, San Jose, CA), centrifugation of the tube after a 15-minute
incubation at room temperature, and removal of the superna-
tant. This step was repeated twice. After two washes in
Ca2/Mg2-free phosphate-buffered saline, the dry granu-
locyte pellet was stored at 20°C until processed. Cy-
tosmears of these cellular preparations routinely showed a
granulocyte content greater than 95%. DNA was extracted
using the QIAmp DNA blood kit (Qiagen, GmbH, Hilden,
Germany) and quantified using the NanoDrop technology
(ND-1000 spectrophotometer; NanoDrop Technology, Wil-
mington, DE). All samples used for real-time PCR had 260:
280 ratios greater than 1.8.
Real-Time PCR Assay Development
MPL maps to human chromosome 1p33–34.2. GenBank
sequence AL139289 was used for the design of primers
and probes according to the Primer 3 software at http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi; accessed
January 2007 and the MELT-CALC (version 2.0) software at
http://www.meltcalc.de; accessed January 2007. The Tm of
the locked nucleic acid (LNA) probes was verified using
Exiqon Tm prediction (http://lna-tm.com; accessed March
2007). Sequences of primers and probes are provided in
Table 1. This assay makes use of a single set of primers,
Table 1. Sequences of Primers and Probes Used for
Real-Time PCR Assay of the MPLW515L or W515K
Mutation
Real-time PCR
primers/probes Sequence
MPL forward primer 5-agcctggatctccttggtgac-3
MPL reverse primer 5-accgccagtctcctgcct-3
MPL wild-type probe 5-ctgctgAggtGgcAgtttc-3
MPL 515WL probe 5-ctgcTgaggTTgcag
TTtc-3
MPL 515WK probe 5-tgcTgctgaggAAg
cagtttcc-3
LNA bases are indicated by a capital letter with a plus sign before
it. Probes were labeled with 5-carboxyfluorescein at their 5 termini
while Black Hole Quencher-1 was attached to the 3 termini. The
underlined nucleotides correspond to the 515 codon; the wild-type
sequence is TGG, the W515L sequence is TTG, and the W515K
sequence is AAG.
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with the advantage that amplification of mutant and wild-
type alleles has the same efficiencies, while specificities
are obtained with different probes that were modified
according to the LNA chemistry (Sigma-Proligo, Paris,
France).
Real-time PCR was performed using both the ABI
Prism 7000 platform and the StepOne real-time PCR sys-
tem (Applied Biosystems, Foster City, CA) with similar
results. Forty nanograms of granulocyte DNA were used
in each real-time PCR assay. Three different real-time
reactions were set up in triplicate (one each for W515L,
W515K, and wild-type control) for each DNA sample. A
20-l reaction contained 1X TaqMan universal PCR Mas-
ter Mix (Applied Biosystems), 300 nmol/L each primer,
and 200 nmol/L each LNA-modified probe. Control wells
without template (NTC) were included in each assay.
Amplification and detection were performed under the
following conditions: initial hold at 50°C for 2 minutes,
hold at 95°C for 10 minutes followed by 55 cycles at 95°C
for 15 seconds and 66°C or 62°C for 1 minute for the case
of MPL unmutated and W515L probe or W515K probe,
respectively. The fluorescent signal intensities were re-
corded and analyzed during PCR amplification using the
SDS software (Applied Biosystems). The mean CT of
triplicate determinations (CT
MPLW515L/K  CT
MPLwild-type)
was calculated, and the percentage of mutant alleles in
the sample was obtained by comparison with a reference
curve of serial dilutions of mutant plasmid mixtures in
wild-type plasmid DNA. Both positive and negative con-
trols were included in each assay.
Preparation of Cloned MPL Fragments
To prepare a reference curve for the quantification of the
mutant alleles, a 277-bp fragment of MPL from healthy
subjects (wild-type sequence) or from patients harboring
either the W515L or W515K mutation was subcloned into
the pCR2.1 TOPO vector using the TOPO TA cloning
kit (Invitrogen, Groningen, The Netherlands). The se-
quences of the forward and reverse primers for PCR were
5-TGGGCCGAAGTCTGACCCTTT-3 and 5-AGAGGT-
GACGTGCAGGAAGTGGCGAAGC-3, respectively. Re-
combinant plasmids were isolated and bi-directional se-
quencing was performed to validate the sequences
before plasmid amplification. A dilution of the stock plas-
mid solution was prepared and preliminarily tested ac-
cording to the standardization principles described in the
Final Report on Plasmid Standards for Real Time PCR
and GM Enforcement Testing developed by Department
for Environment, Food, and Rural Affairs of the govern-
ment of the United Kingdom at http://www.g-inspectorate.
gov.uk/documents/PLASMID.pdf; accessed July 2007.
Comparison of Conventional Sequencing and
Real-Time PCR Assay
DNA samples from 217 patients with myelofibrosis were
genotyped for theMPLW5151L/K mutation using conven-
tional sequencing. MPL mutation sequencing was per-
formed by amplifying a 248-bp region of MPL exon 10
using the following primers: forward, 5-TAGCCTG-
GATCTCCTTGGTG-3 and reverse, 5-AGAGGTGACGT-
GCAGGAAGT-3. PCR products were subjected to bidi-
rectional sequencing analysis using an ABI PRISM
3730DNA Analyzer (Applied Biosystems, Foster City, CA)
as described.26
Results
In preliminary experiments we attempted to conduct a
real-time PCR assay for the MPLW515L/K allele using
conventional 5-5-carboxyfluorescein- and 3-Black Hole
Quencher-1-labeled probes, with lengths varying from 16
to 28 bp; these probes were differentially spaced along
the mutation site. However, we failed to obtain satisfac-
tory results due to a high background generated by
nonspecific binding of the probes for mutant alleles to the
wild-type sequence (not shown in detail). Therefore, we
subsequently explored the use of LNA-modified probes
because of their anticipated greater specificity of hybrid-
ization and thermal stability. Both the primers and LNA
probes, listed in Table 1, were chosen for their optimal
performance among other sequences and were used in
all of the experiments described herein. These probes
were derived from a 28-bp probe originally designed for
conventional PCR, progressively shortened by the intro-
duction of LNA residues at various positions so that the
final calculated Tms of the individual probes were simi-
lar.30 The Tms of the probes selected from a panel of five
different sets that were experimentally tested in real-time
PCR assays were 73°C, 74°C, and 72°C for the wild-type,
W515L, and W515K probes, respectively. The probe cor-
responding to codon 515 had two LNA nucleotides for
the mutant sequences and one LNA base in the wild-type
sequence (underlined in Table 1). In our original assay
design, we performed single real-time PCRs for each of
these probes, all labeled with 5-carboxyfluorescein; how-
ever, subsequent experiments showed that comparable
results could be obtained by using the 5-carboxyfluores-
cein-labeled wild-type probe with one of the 5-VIC-la-
beled mutant probes in the same reaction tube. Results
presented in this manuscript were obtained using the
single-probe assay.
Standard curves were constructed for the wild-type
and mutated sequences using serial dilutions of cloned
MPL fragments in the range of 1 to 106 copies; amplifi-
cation plots and corresponding regression lines are pre-
sented in Figure 1. As suggested by the slope of the
curves, the efficiency of real-time PCR was almost abso-
lute. Next, we performed progressive dilutions of each
mutant plasmid allele, from 0.1% to 100%, in a solution of
wild-type plasmid allele as in nonhomogeneous DNA
samples used for diagnostic purposes. Figure 2 shows
assay performance for the W515L and W515K alleles,
which reproducibly allowed for the detection of at least
0.1% mutated allele in a wild-type background. This sen-
sitivity level could be attained using 40 ng of genomic
DNA from diagnostic samples, based on a 3.7 pg of DNA
content per human haploid cell. To ascertain whether a
similar level of sensitivity could be obtained in clinical
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samples, dilution experiments were also performed using
100% of mutated W515K or W515L patient DNA in an
wild-type control DNA sample. As shown in Figure 3, the
assay performance in genomic DNA samples was super-
imposable on the standard reference curve generated
with plasmid DNA, suggesting that that 0.1% mutant
allele could be reproducibly detected in granulocyte
DNA samples.
The intra-assay variation coefficient was calculated us-
ing DNA samples from 10 control subjects and four pa-
tients with either the W515L or W515K mutation and
assayed in triplicate in the same plate. The variation in the
calculated percentage of mutant allele was less than 2%
and 1% for the W515L and W5151K allele, respectively,
while no control well was positive. The interassay varia-
tion test was performed using DNA samples from two
patients, each with a 100%W515L or W515K allele, either
undiluted or diluted in normal DNA to 10 and 50% of the
mutant allele. These reference samples were analyzed in
10 different runs over a 3-month period, and the variation
in the percentage of mutant allele was less than 2.5% for
both mutated alleles. Therefore, this high reproducibility
and the comparable performance of the reference curves
obtained with plasmid or patient DNA (Figure 3) suggests
that the assay does not require a standard curve for each
run, but that the percentage of mutated allele in clinical
samples may be obtained directly by the CT calculation.
Under these experimental conditions, we evaluated
sixty healthy blood donors, and none was found to have
MPL mutant cells. Similarly, none of the 50 patients with
PV had the MPLW515 mutation. We analyzed a popula-
tion of 217 patients with myelofibrosis, both primary and
secondary forms, who were previously genotyped using
conventional bi-directional sequencing; this series has
been already reported.26 According to sequencing re-
sults, nine patients presented with the W515L allele, eight
patients had the W5151K allele, and one patient had both
the W515L and W515K mutant alleles. Unfortunately, we
were unable to collect fresh cells from this subject to
evaluate whether these two mutations were either har-
bored simultaneously by a single cell or involved two
different clonogenic progenitors. All patient results were
confirmed using the novel real-time PCR assay. However,
an additional patient who had been considered wild type
using the sequencing approach was actually found to
harbor low levels of the W515L allele (1.5%) by real-time
PCR, and was accordingly rediagnosed as an MPL mu-
tant. The mean calculated burden of MPL mutant alleles
using real-time PCR was 51  15% (range, 1.5–100%),
not statistically different from that calculated using peak
area integration of the chromatogram (55  20%; range,
19–100%).
Discussion
Currently, genotyping of MPL mutations is performed
using conventional bidirectional sequencing, a method
that has a detection limit of 10 to 15%, is time consuming,
and is relatively expensive; thus, it is not suitable for wide
population screening. A melting curve technique, with a
sensitivity of 3 to 5%, has also been described.25 We
have developed a novel method for the detection and
quantification ofMPLW515L/K mutations that is based on
LNA probes for real-time PCR. LNA probes have in-
creased thermal stability and hybridization specificity
Figure 1. Amplification plots of wild-type and mutated MPLW515L and W515K alleles in the real-time PCR assay. Variations in threshold cycle reflected different
input copy numbers of the respective cloned plasmids in the range of 1 to 106 copies. Linear regression analysis between the input number of copies and the CT
value is presented in the lower part of the figure.
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due to their higher Tm, making them especially suitable
for allelic discrimination.31 Indeed, LNA chemistry was
key to the development of our assay in which a number of
conventional TaqMan probes tested initially displayed
very poor specificity. Using the optimized conditions de-
scribed here, we were able to attain a sensitivity level of
at least 0.1% mutant allele in a wild-type background, a
value that is at least 100-fold higher than conventional
sequencing. This high sensitivity of the assay is of par-
ticular relevance in the setting of myeloproliferative dis-
orders in which only a proportion of hematopoietic clones
and their differentiated progeny might harbor MPL muta-
tions. It is also conceivable that the true incidence ofMPL
mutations in myeloproliferative disorders has been un-
derestimated in previous studies where direct sequenc-
ing or melting curves were used for genotyping.17,25 As a
matter of fact, one patient in this series who had been
considered wild-type MPL using sequencing26 harbored
a low W515L allele burden by real-time PCR. Further-
more, in a large series of patients with ET, we found that
the frequency of MPL mutations using the real-time PCR
assay was sevenfold higher than originally reported.25,30
The studies described herein have been conducted on
purified granulocytes; due to the retrospective design of
the study, we do not have stored samples of whole blood
or bone marrow to perform comparative analyses among
these different cellular sources. However, even in the
case of JAK2V617F genotyping, it is still unknown
whether fewer homogeneous cellular samples compared
with granulocytes might be equally informative.33 In our
opinion, purified blood granulocytes remain the most ap-
propriate DNA source for genotyping in myeloprolifera-
tive disorders.36
In summary, we have developed a sensitive and con-
venient method for the detection and quantification of
mutant alleles atMPL codon 515 based on real-time PCR
in the presence of LNA-modified probes. This methodol-
ogy is expected to facilitate the screening of MPL muta-
Figure 2. Performance of the real-time PCR assay for quantification of the
MPLW515L (upper panel) or W515K (lower panel) allele; curves were ob-
tained by the progressive dilution of each mutated plasmid DNA in wild-type
plasmid DNA. The SD of each experimental point was less than 4% in three
individual real-time PCR assays and was not reported. The inset in each plot
shows the sensitivity of the assay in the 0 to 1% mutant allele range and
represents the mean (SD) of five different preparations. *P  0.01; **P 
0.001 compared with the 0 point.
Figure 3. Comparative performance of the real-time PCR assay for quantifi-
cation of the MPLW515L (upper panel) or W515K (lower panel) allele using
plasmid DNA (circles) or patient DNA (gDNA; squares); curves were ob-
tained by the progressive dilution of either each mutated plasmid DNA in
wild-type plasmid DNA or a 100% mutated W515L or W515K patient in
wild-type control DNA. The insert in each plot shows the sensitivity of the
assay in the 0 to 1% mutant allele range and represents the mean of four
different preparations. The SD of each experimental point was less than 3%
and was not reported. *P  0.01; **P  0.001 compared with the 0 point.
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tions in large patient series, helping to molecularly clas-
sify patients with ET or PMF and possibly provide a
prognosis.26 In addition, this approach might be useful
for measuring changes in mutant allele burdens in pa-
tients who will receive, in the near future, novel targeted
drugs against MPL mutant cells and/or components of
the JAK/STAT pathway, as well as in assisting disease
monitoring after hematopoietic stem cell transplantation
in myelofibrosis as described for the JAK2V617F muta-
tion.35 However, assessment of the role of the MPLW515
mutant allele-burden quantification as a biomarker of dis-
ease or minimal residual disease will require prospective
studies.
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